

## Topical Collection

# Application of Natural and Pseudo Natural Products in Drug Discovery and Development

### Message from the Collection Editor

Natural products (NPs) and NP-based semi-synthetic compounds have recently regained increased attention by the scientific community due to their great structural and chemical diversity. Notably, NP-based molecules are valid sources for drug lead compounds because 60% of chemotherapeutic agents originate from natural products. On the other hand, pseudo-natural products (PNPs) combine natural product (NP) fragments in novel and intriguing arrangements which are not accessible via biosynthesis pathways. Moreover, they can be regarded as non-biogenic fusions of NP-derived fragments. Scientists have established new synthesis principles to go beyond the chemical space explored by nature by combining the principles of biology-oriented synthesis (BIOS) and fragment-based compound design. Interestingly, scaffolds from different NPs are combined and reconnected into new alternative molecular scaffolds, so-called pseudo-natural products. The aim of this topical collection on natural product (NP)- and pseudo-natural product (PNP)-based drug discovery is to underline the most recent discoveries and progress in all fields of biological sciences dealing with NPs and PNPs.

---

### Collection Editor

Dr. Hidayat Hussain

Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry, Weinberg 3, D-06120 Halle (Salle), Germany

---



## Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/88421](https://mdpi.com/si/88421)

*Current Issues in Molecular Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
cimb@mdpi.com

[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,  
Christchurch 8140, New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.